Aduro Biotech (ADRO) Tops Q3 EPS Views; Receives EMA Orphan Drug Designation for CRS-207
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Aduro Biotech (ADRO) Tops Q3 EPS Views; Receives EMA Orphan Drug Designation for CRS-207
November 23, 2015 8:02 AM EST
BERKELEY, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 for the treatment of malignant pleural mesothelioma (MPM).
The receipt of Orphan Drug Designation in the European Union (EU) for CRS-207 for the treatment of MPM marks a significant regulatory milestone for Aduro, as we expand our operations in Europe and advance our therapies closer to the commercial marketplace, said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. We look forward to working with the EMA to... More
November 23, 2015 8:02 AM EST
BERKELEY, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter and nine months ended September 30, 2015. Net income was $0.6 million for the third quarter of 2015, or $0.01 per share, and net loss was $42.3 million, or $1.09 per share, for the nine months ended September 30, 2015. This compares to a net loss of $4.7 million, or $14.24 per share, and $16.1 million, or $52.47 per share respectively, for the same periods in 2014.Â
Cash, cash equivalents and marketable securities totaled $448.4 million at September 30, 2015, compared to $119.5 million at December 31, 2014.Â
We believe a major... More
